About Cytoki
The Cytoki Story
Cytoki Pharma is a biotechnology company focused on serious diseases caused by epithelial injury with unmet medical need. The company was founded in 2019 after licensing of full pharma program from Novo Nordisk with seed financing from Lundbeckfonden Emerge, followed by a $45 M series A from a syndicate of strong international investors. Cytoki is run by a team of experienced pharma executives with deep expertise in IL-22 biology, lipidation technology and drug development. Our long-acting lipidated IL-22 analogue program with promise as treatment for diseases involving epithelial injury - particularly IBD - is on track for Phase 1 start in late 2022.
Our team
Rasmus Jorgensen, PhD
CEO
Anne Louise Kjølbye, PhD, MBA
Chief Development Officer
Martijn van de Bunt, MD, DPhil
Vice President of Research
Jens Chr. Norrild, PhD
Vice President of CMC
Karsten Skydsgaard, DVM, E*MBA
Head of Non-Clinical Development
Our board
Christian Elling
Chairperson and Managing Partner, Lundbeckfonden BioCapital
Karen Wagner
Managing Partner, Ysios Capital
Dani Bach
Partner, +ND Capital
Amanda Chaperot
Partner, Seventure Partners
Our investors
